Enhancing the Room-Temperature Phosphorescence Performance by Salinization of Guests.

Although the host-guest doped strategy effectively improves the phosphorescence performance of materials and greatly enriches the variety of materials, most of the guests are organic molecules with weak luminescence ability, which leads to the need for further improvement in the phosphorescence performance of doped materials. Herein, by salinization of organic molecules, the luminescence performance of the guests was effectively improved, thereby significantly enhancing the phosphorescence performance of the doped system. A compound 4-(naphthalen-2-yl)quinoline (QL) containing nitrogen atom was synthesized as initial guest, then QL was salted to obtain six organic salt guests containing anions BF4-, PF6-, CF3SO3-, N(CF3SO2)2-, ClO4-, and C4F9SO3-, respectively. Two doped systems were constructed using benzophenone and poly(methyl methacrylate) as the hosts. The phosphorescence quantum yield and phosphorescence lifetime of doped materials with QL as guest were only 4.1%/5.2% and 131 ms/141 ms, while those of doped materials with salinized molecules as guests were improved to 32-39% and 534-625 ms, respectively. The single-crystal structures and theoretical calculations indicated that anions can not only enhance the intermolecular interaction of guests but also increase the spin-orbit coupling constant. This work provides an effective strategy for improving the phosphorescence performance of doped materials.

The safety and efficacy of indobufen or aspirin combined with clopidogrel in patients with acute myocardial infarction after percutaneous coronary intervention.

Currently, the standard treatment for patients who have undergone percutaneous coronary intervention (PCI) following acute myocardial infarction (MI) involves dual antiplatelet therapy (DAPT) with a combination of aspirin and a potent P2Y12 receptor inhibitor. However, the potential benefits of aspirin were partially constrained by the intolerance of some patients. The safety and efficacy of indobufen, an alternative antiplatelet agents to aspirin, in patients with AMI after PCI are yet to be thoroughly investigated.This retrospective study was conducted at a single center and utilized propensity score matching. The enrollment spanned from January 2019 to June 2022, incorporating patients with AMI after PCI. The participants were categorized into two groups based on discharged prescriptions: the aspirin DAPT group and the indobufen DAPT group. The primary endpoint focused on net adverse clinical event (NACE), defined as a composite outcome, including cardiac death, recurrence of MI, definite or probable stent thrombosis (ST), target lesion revascularization (TLR), ischemic stroke and Bleeding Academic Research Consortium (BARC) criteria type 2, 3, or 5. All the patients underwent a one-year follow-up period.A total of 1451 patients were enrolled in this study, with 258 assigned to the indobufen DAPT group and 1193 to the aspirin DAPT group. Following 1:1 propensity score matching, 224 patients were retained in each group. In the indobufen DAPT group, 58 individuals (25.9%) experienced the primary endpoint within one year, compared to 52 individuals (23.2%) in the aspirin DAPT group (HR 1.128, 95% CI 0.776-1.639, p = .527). Specifically, no significant differences were observed in either the efficacy endpoint (MACCE, 20.1% vs. 14.7%, HR 1.392, 95% CI 0.893-2.170, p = .146) or the safety endpoint (BARC 2,3 or 5, 8.04% vs. 10.30%, HR 0.779, p = .427). These findings remained consistent at 1, 3, or 6 months. Additionally, the incidence of gastrointestinal symptoms were significantly lower in indobufen DAPT group compared to the aspirin DAPT group (7.1% vs. 14.3%, p = .022).Our research reveals that the efficacy and safety of indobufen are comparable to aspirin in Chinese patients with AMI following PCI. Given the potential advantages of indobufen in alleviating gastrointestinal symptoms, we propose it as a viable alternative for individuals intolerant to aspirin.

What is the context? Currently, the standard treatment for patients who have undergone percutaneous coronary intervention following acute myocardial infarction involves dual antiplatelet therapy with a combination of aspirin and a potent P2Y12 receptor inhibitor.However, the potential benefits of aspirin were partially constrained by the intolerance of some patients.The safety and efficacy of indobufen, an alternative antiplatelet agents to aspirin, in patients with AMI after PCI are yet to be thoroughly investigated.What is new? While both American and European clinical guidelines recommend the use of indobufen as an alternative treatment for patients who cannot tolerate aspirin, there exists a limited body of research on this subject.Our research is the first to address this gap by comparing the efficacy and safety of indobufen and aspirin in patients with AMI.Our research reveals that the efficacy and safety of indobufen are comparable to aspirin in Chinese patients with AMI following PCI. Given the potential advantages of indobufen in alleviating gastrointestinal symptoms, we propose it as a viable alternative for individuals intolerant to aspirin.What is the impact? These findings might pave the way for further exploration of alternatives to aspirin in patients with AMI.

Recent progress in ion-regulated organic room-temperature phosphorescence.

Organic room-temperature phosphorescence (RTP) materials have attracted considerable attention for their extended afterglow at ambient conditions, eco-friendliness, and wide-ranging applications in bio-imaging, data storage, security inks, and emergency illumination. Significant advancements have been achieved in recent years in developing highly efficient RTP materials by manipulating the intermolecular interactions. In this perspective, we have summarized recent advances in ion-regulated organic RTP materials based on the roles and interactions of ions, including the ion-π interactions, electrostatic interactions, and coordinate interactions. Subsequently, the current challenges and prospects of utilizing ionic interactions for inducing and modulating the phosphorescent properties are presented. It is anticipated that this perspective will provide basic guidelines for fabricating novel ionic RTP materials and further extend their application potential.

Twofold rigidity activates ultralong organic high-temperature phosphorescence.

A strategy is pioneered for achieving high-temperature phosphorescence using planar rigid molecules as guests and rigid polymers as host matrix. The planar rigid configuration can resist the thermal vibration of the guest at high temperatures, and the rigidity of the matrix further enhances the high-temperature resistance of the guest. The doped materials exhibit an afterglow of 40 s at 293 K, 20 s at 373 K, 6 s at 413 K, and a 1 s afterglow at 433 K. The experimental results indicate that as the rotational ability of the groups connected to the guests gradually increases, the high-temperature phosphorescence performance of the doped materials gradually decreases. In addition, utilizing the property of doped materials that can emit phosphorescence at high temperatures and in high smoke, the attempt is made to use organic phosphorescence materials to identify rescue workers and trapped personnel in fires.